nazartinib

Ligand id: 9204

Name: nazartinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 83.36
Molecular weight 494.22
XLogP 3.66
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
N-{7-chloro-1-[(3R)-1-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-1H-1,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide
International Nonproprietary Names
INN number INN
10259 nazartinib
Synonyms
compound 47 [PMID: 27433829] | EGF-816 | EGF816
Database Links
PubChem CID 72703790
Search Google for chemical match using the InChIKey IOMMMLWIABWRKL-WUTDNEBXSA-N
Search Google for chemicals with the same backbone IOMMMLWIABWRKL
Search PubMed clinical trials nazartinib
Search PubMed titles nazartinib
Search PubMed titles/abstracts nazartinib
Search UniChem for chemical match using the InChIKey IOMMMLWIABWRKL-WUTDNEBXSA-N
Search UniChem for chemicals with the same backbone IOMMMLWIABWRKL
Comments
EGF816 is an irreversible and selective inhibitor of EGFRs harbouring gatekeeper T790M, and sensitising L858R mutations, whilst sparing the wild-type receptor (such compounds are termed third generation EGFR tyrosine kinase inhibitors) [3]. It has been developed to overcome acquired resistance to, and side-effect liabilities of first and second generation EGFR inhibitors in non-small-cell lung cancer (NSCLC). Small-molecule EGFR T790M inhibitors and the development of novel compounds in the discovery pipeline are reviewed by Song et al. (2016) [5].
EGF816 is claimed in Novartis' patent WO2015085482 [4], where it is named (R,E)-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol-2-yl)-2-methylisonicotinamide, which resolves to the IUPAC name presented here.
Preclinical characterisation is reported in [1].